News By Tag * Pharmaceutical * Healthcare * Ratings * Astellas * Drug * Regulatory * Disease * Reimbursement * Drugmakers * Japanese * More Tags... Industry News Country(s) Industry News
| New Market Research Report: Japan Pharmaceuticals & Healthcare Report Q3 2010New Healthcare market report from Business Monitor International: "Japan Pharmaceuticals & Healthcare Report Q3 2010"
Despite this downgrade, Japan remains a prime market for research-based drugmakers. Combined sales of prescription and over-the-counter (OTC) medicines are forecast to increase from JPY9,040bn (US$95.2bn) in 2009 to JPY9,166bn (US$89.9bn) in 2010. This makes the market the second largest globally, behind the US. However, factors impairing market access include a protracted approvals system, biennial price cuts and the long-standing requirement to conduct local clinical trials. Foreign firms should also be aware of a weakening yen in 2010 and 2011. The entry of Japanese technology companies into the global healthcare sector is a key trend to emerge during the first half of 2010. In February, Fujifilm revealed that it would develop generic drugs. In March, Hitachi said it would assist local drugmakers with regulatory submissions. In April, Fujitsu unveiled a disease diagnostic. Later that month, Panasonic announced that is Singapore research and development centre would start investigating medical innovations. It is BMI's view that all four companies view the healthcare sector as a sustainable business that is resistant to economic downturns, as has been recently demonstrated. In April 2010, local firm Eisai said it would cut the price of its Alzheimer's disease therapeutic Aricept (donepezil) in six Asian countries. BMI notes that this tactic is in accordance with one of our short-term core views: drugmakers will increasingly use differential pricing in emerging markets. However, we do not expect the Japanese drugmaker to see a significant upside. The product's patent expires soon and Eisai has very limited experience in developing countries. Therefore, the Tokyo-based firm will find market access challenging. Large Japanese pharmaceutical companies have traditionally focused on the domestic market. However, due to challenging operating conditions, most are looking abroad for growth. In May 2010, local firm Astellas agreed to buy US-based OSI Pharmaceuticals for US$4bn in cash. Astellas offered US$57.50 per share, representing a premium of 55% on the closing price of OSI's shares - US$37.02 on February 26 2010 - the day before the announcement of Astellas's tender offer. Despite the high premium paid, BMI believes the acquisition is a sound move by Astellas, which hopes to add JPY34.0bn (US$370mn) in revenue in the year to March 2011. For more information or to purchase this report, go to: - http://www.fastmr.com/ Report Table of Contents: Executive Summary SWOT Analysis - Japan Pharmaceuticals And Healthcare Industry SWOT - Japan Political SWOT - Japan Economic SWOT Pharmaceutical Business Environment Ratings - Table: Asia Pacific - Regional Pharmaceutical Business Environment Ratings, Q310 - Limits of Potential Returns - Risks to Realisation of Returns Japan - Market Summary - Regulatory Regime - Recent Regulatory Developments - Intellectual Property Developments - Pricing and Reimbursement System - Table: Reimbursement Categories And Rates - Recent Pricing and Reimbursement Developments - Other Regulatory Issues - Table: Concerns Of Pharmaceutical Associations Industry Trends and Developments - Epidemiology - Non-Communicable Diseases - Communicable Diseases - Mental Health - Healthcare Sector - Healthcare Sector Financing - Healthcare Reforms - International Reaction - Medical Devices Industry Forecast Scenario - Overall Market Forecast - Key Growth Factors - Industry - Macroeconomic Outlook - Table: Japan - Economic Activity - Prescription Drug Market Forecast - Patented Drug Market Forecast - Generic Drug Market Forecast - OTC Market Forecast - Medical Device Market Forecast - Pharmaceutical Trade Forecast - Other Healthcare Data And Forecasts - Key Risks to BMI's Forecast Scenario Competitive Landscape - Foreign Generic Drug Sector - Recent Company Activities - Pharmaceutical Wholesale and Retail Company Profiles - Indigenous Manufacturers - Takeda Pharmaceutical Company - Astellas - Eisai - Daiichi Sankyo - Mitsubishi Tanabe - Sawai Pharmaceutical - Leading Foreign Manufacturers - Pfizer - Sanofi-Aventis - Merck & Co (Banyu) - Novartis - GlaxoSmithKline (GSK) - AstraZeneca BMI Methodology - How We Generate Our Pharmaceutical Industry Forecasts - Pharmaceutical Business Environment Ratings Methodology - Ratings Overview - Table: Pharmaceutical Business Environment Indicators - Weighting - Table: Weighting Of Components - Sources About Business Monitor International Business Monitor International (BMI) offers a comprehensive range of products and services designed to help senior executives, analysts and researchers assess and better manage operating risks, and exploit business opportunities, across 175 markets. BMI offers three main areas of expertise: Country Risk BMI's country risk and macroeconomic forecast portfolio includes weekly financial market reports, monthly regional Monitors, and in-depth quarterly Business Forecast Reports. Industry Analysis BMI covers a total of 17 industry verticals through a portfolio of services, including in-depth quarterly Country Forecast Reports. View more research from Business Monitor International at http://www.fastmr.com/ About Fast Market Research Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156. End
|
| |||||||||||||||||||||||||||||||||||||||||||||
Account Phone Number